- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07600229
Barefoot Walking VS Standardised Conservative Care for Plantar Fasciopathy
Clinical and Economic Effectiveness of Barefoot Walking Compared to Standardised Conservative Care for the Treatment of Plantar Fasciopathy: a Pragmatic Randomised Controlled Trial
The goal of this clinical trial is to learn if a barefoot walking programme can treat plantar fasciopathy (heel pain) in adults aged 18-70. The main questions it aims to answer are:
- Does a barefoot walking programme reduce heel pain compared to a standardised stretching and strengthening programme?
- Does a barefoot walking programme improve foot function and quality of life in adults with plantar fasciopathy?
Researchers will compare a barefoot walking programme to a standardised stretching and strengthening programme to see if barefoot walking is an effective conservative management approach for plantar fasciopathy.
Participants will:
- Be randomly assigned to either a barefoot walking programme or a stretching and strengthening programme
- Complete a 12-week home-based exercise programme
- Complete short weekly questionnaires throughout the 12 weeks
- Complete 3 follow-up surveys over 6 months after the intervention ends
- Receive education on load management and plantar fasciopathy
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Carlow County
-
Carlow, Carlow County, Irlanda, R93 V960
- Reclutamiento
- South East Technological University
-
Contacto:
- Elisabetta Brigo, PhD Researcher, MSc, BSc
- Número de teléfono: +39 3450498301
- Correo electrónico: c00315626@setu.ie
-
Investigador principal:
- Elisabetta Brigo, PhD Researcher, MSc, Bsc
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Aged 18-70 years;
- Clinical diagnosis of Plantar Fasciopahty, defined by: a) Pain localised to the medial calcaneal tubercle of sharp or stabbing quality; b) Pain worst with the first few steps in the morning or after a period of rest (first-step pain); c) Pain reproduced with palpation of the medial calcaneal tubercle OR positive Windlass Test;
- Symptom duration greater than 4 weeks;
- Able to walk independently without a mobility aid
- Able to provide informed consent and comply with study protocol
Exclusion Criteria:
- Prior surgery on the affected foot
- Diabetes with peripheral neuropathy or other neurological condition affecting lower limb sensation or motor control
- Active inflammatory arthropathy, uncontrolled vascular disease, or inability to walk unaided
- Current or recent (less than 6 months) bony stress fracture or other acute foot or ankle injury on the affected side
- Pregnancy during the intervention period
- BMI greater than 40 kg/m²
- Corticosteroid injection to the affected foot within the previous 3 months
- Night splints initiated less than 4 weeks prior to enrolment
- Any condition that would make participation unsafe, including open foot wounds
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Barefoot Walking
Participants allocated to this arm will follow a structured 12-week progressive barefoot walking programme on grass completed at home.
The programme involves gradually increasing the duration and frequency of barefoot walking on grass.
Participants will receive education on plantar fasciopathy, load management principles, and guidance on how to progress the programme safely.
Adherence and symptom response will be monitored through weekly short questionnaires.
|
A structured 12-week progressive home-based barefoot walking programme on grass for adults with plantar fasciopathy.
Participants gradually increase the duration and frequency of barefoot walking over the 12-week period.
Education on plantar fasciopathy and load management principles is provided.
Adherence and symptom response are monitored via weekly questionnaires.
Otros nombres:
|
|
Comparador activo: Standardised Conservative Care
Participants allocated to this arm will follow a structured 12-week standardised stretching and strengthening programme completed at home.
The programme includes plantar fascia and calf stretching exercises alongside progressive foot and lower limb strengthening exercises.
Participants will receive education on plantar fasciopathy and load management principles.
Adherence and symptom response will be monitored through weekly short questionnaires.
|
A structured 12-week standardised home-based stretching and strengthening programme for adults with plantar fasciopathy.
The programme includes plantar fascia and calf stretching alongside progressive foot and lower limb strengthening exercises.
Education on plantar fasciopathy and load management principles is provided.
Adherence and symptom response are monitored via weekly questionnaires
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
First-Step Pain
Periodo de tiempo: From the baseline assessment (Week 0) until end of intervention (Week 12)
|
Changes in average first-step morning pain over the last 7 days measured with the Numeric Pain Rating Scale (NPRS), where 0 = no pain and 10 = worst imaginable pain.
|
From the baseline assessment (Week 0) until end of intervention (Week 12)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adherence
Periodo de tiempo: Weekly during the 12-week intervention period.
|
Percentage of prescribed home exercise sessions completed, recorded via participant self-report log throughout the 12-week intervention period.
|
Weekly during the 12-week intervention period.
|
|
Cost-Effectiveness (Incremental Cost-Effectiveness Ratio)
Periodo de tiempo: At week 12 and at 6 months post-intervention (week 36).
|
Incremental cost per unit of clinical improvement between groups, expressed as cost per 1-point improvement in pain (NPRS) and cost per 10% improvement in foot function (FFI).
Total costs will include healthcare utilisation and participant out-of-pocket expenses.
Two separate ICERs will be calculated.
|
At week 12 and at 6 months post-intervention (week 36).
|
|
Adverse Events
Periodo de tiempo: Throughout the 12-week intervention and at 2, 4, and 6 months post-intervention.
|
Any training-related injuries, falls, skin injuries, or symptom exacerbations reported by participants throughout the study period, recorded via weekly questionnaires and follow-up surveys.
|
Throughout the 12-week intervention and at 2, 4, and 6 months post-intervention.
|
|
Function
Periodo de tiempo: From baseline (Week 0) until the end of intervention (Week 12)
|
Changes in foot function measured with the Foot Function Index (FFI).
Higher scores indicate worse function.
|
From baseline (Week 0) until the end of intervention (Week 12)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SETU/REC/25/26/050
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .